<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Aptose Biosciences, Inc.

    Aptose Biosciences, Inc.

    Aptose Biosciences is a clinical-stage biotechnology company developing personaliz...

    Aptose Biosciences is a clinical-stage biotechn...

    Filing Type:    PU
    Gritstone Oncology, Inc.

    Gritstone Oncology, Inc.

    Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight mu...

    Gritstone Oncology is developing tumor-specific...

    Filing Type:    PU
    BioSig Technologies, Inc.

    BioSig Technologies, Inc.

    BioSig Technologies is a medical device company developing a proprietary technolog...

    BioSig Technologies is a medical device company...

    Filing Type:    PU
    NeuroMetrix, Inc.

    NeuroMetrix, Inc.

    Founded in 1996 as a spinoff from the Harvard-MIT Division of Health Sciences and ...

    Founded in 1996 as a spinoff from the Harvard-M...

    Filing Type:    PU
    Bio-Path Holdings, Inc.

    Bio-Path Holdings, Inc.

    Bio-Path is a biotechnology company developing targeted therapies for acute myeloi...

    Bio-Path is a biotechnology company developing ...

    Filing Type:    PU
    Nuvectra Corporation

    Nuvectra Corporation

    NuvectraÂŽ is a neurostimulation company committed to helping physicians improve t...

    NuvectraÂŽ is a neurostimulation company commit...

    Filing Type:    PU
    HOOKIPA Pharma Inc.

    HOOKIPA Pharma Inc.

    HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new...

    HOOKIPA Pharma Inc. is a clinical stage biophar...

    Filing Type:    PU
    Jounce Therapeutics, Inc.

    Jounce Therapeutics, Inc.

    Jounce Therapeutics is a clinical stage immunotherapy company dedicated to transfo...

    Jounce Therapeutics is a clinical stage immunot...

    Filing Type:    PU
    OncoSec Medical Incorporated

    OncoSec Medical Incorporated

    OncoSec Medical Incorporated is a clinical-stage biotechnology company focused on ...

    OncoSec Medical Incorporated is a clinical-stag...

    Filing Type:    PU
    Immutep Limited

    Immutep Limited

    We are a biotechnology company developing novel immunotherapy treatments for cance...

    We are a biotechnology company developing novel...

    Filing Type:    PU
    Ourotech, Inc.

    Ourotech, Inc.

    A patient that is diagnosed with cancer today will have a genetic screen on their ...

    A patient that is diagnosed with cancer today w...

    Fundraising Status:    SD
    Filing Type:    CF
    Idera Pharmaceuticals, Inc.

    Idera Pharmaceuticals, Inc.

    Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing nov...

    Idera Pharmaceuticals is a clinical-stage bioph...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.